Sections
| Title | Starting Page | Number of Pages |
|---|
| Table of Contents | 2 | 4 |
| List of Tables | 5 | 1 |
| List of Figures | 5 | 1 |
| Introduction | 6 | 1 |
| Global Markets Direct Report Coverage | 6 | 1 |
| Potassium Voltage Gated Channel Subfamily A Member 3 (Voltage Gated Potassium Channel Subunit Kv1.3 or KCNA3) Overview | 7 | 1 |
| Therapeutics Development | 8 | 4 |
| Potassium Voltage Gated Channel Subfamily A Member 3 (Voltage Gated Potassium Channel Subunit Kv1.3 or KCNA3) Products under Development by Stage of Development | 8 | 1 |
| Potassium Voltage Gated Channel Subfamily A Member 3 (Voltage Gated Potassium Channel Subunit Kv1.3 or KCNA3) Products under Development by Therapy Area | 9 | 1 |
| Potassium Voltage Gated Channel Subfamily A Member 3 (Voltage Gated Potassium Channel Subunit Kv1.3 or KCNA3) Products under Development by Indication | 10 | 2 |
| Potassium Voltage Gated Channel Subfamily A Member 3 (Voltage Gated Potassium Channel Subunit Kv1.3 or KCNA3) Pipeline Products Glance | 12 | 1 |
| Early Stage Products | 12 | 1 |
| Potassium Voltage Gated Channel Subfamily A Member 3 (Voltage Gated Potassium Channel Subunit Kv1.3 or KCNA3) Products under Development by Companies | 13 | 3 |
| Potassium Voltage Gated Channel Subfamily A Member 3 (Voltage Gated Potassium Channel Subunit Kv1.3 or KCNA3) Products under Development by Universities/Institutes | 16 | 2 |
| Potassium Voltage Gated Channel Subfamily A Member 3 (Voltage Gated Potassium Channel Subunit Kv1.3 or KCNA3) Therapeutics Assessment | 18 | 6 |
| Assessment by Monotherapy/Combination Products | 18 | 1 |
| Assessment by Mechanism of Action | 19 | 1 |
| Assessment by Route of Administration | 20 | 2 |
| Assessment by Molecule Type | 22 | 2 |
| Potassium Voltage Gated Channel Subfamily A Member 3 (Voltage Gated Potassium Channel Subunit Kv1.3 or KCNA3) Companies Involved in Therapeutics Development | 24 | 7 |
| Amgen Inc. | 24 | 1 |
| Axxam SpA | 25 | 1 |
| Bionomics Limited | 26 | 1 |
| conoGenetix biosciences GmbH | 27 | 1 |
| Johnson &Johnson | 28 | 1 |
| Kineta, Inc. | 29 | 1 |
| Sevion Therapeutics, Inc. | 30 | 1 |
| Potassium Voltage Gated Channel Subfamily A Member 3 (Voltage Gated Potassium Channel Subunit Kv1.3 or KCNA3) Drug Profiles | 31 | 17 |
| BNC-164 Drug Profile | 31 | 1 |
| cgtx-A Drug Profile | 32 | 1 |
| cgtx-F Drug Profile | 33 | 1 |
| cgtx-G Drug Profile | 34 | 1 |
| dalazatide Drug Profile | 35 | 5 |
| KPI-150 Drug Profile | 40 | 1 |
| KPI-190 Drug Profile | 41 | 1 |
| OSK-1 Drug Profile | 42 | 1 |
| Recombinant Peptide to Block Kv1.3 Ion Channel for Autoimmune Diseases Drug Profile | 43 | 1 |
| Recombinant Peptides to Block Kv1.3 Channel for Autoimmune Diseases Drug Profile | 44 | 1 |
| Small Molecules to Block Kv1.3 Ion Channel for Multiple Sclerosis, Immunology, Inflammatory Bowel Disease and Type 1 Diabetes Drug Profile | 45 | 1 |
| SVN-001 Drug Profile | 46 | 1 |
| Synthetic Peptides to Block Potassium Voltage-Gated Channel Subfamily A Member 3 (Kv1.3) for Autoimmune Disorders Drug Profile | 47 | 1 |
| Potassium Voltage Gated Channel Subfamily A Member 3 (Voltage Gated Potassium Channel Subunit Kv1.3 or KCNA3) Dormant Projects | 48 | 2 |
| Potassium Voltage Gated Channel Subfamily A Member 3 (Voltage Gated Potassium Channel Subunit Kv1.3 or KCNA3) Featured News &Press Releases | 50 | 10 |
| Jun 10, 2016: Alliance for Children Therapeutics Presents Dalazatide Data Demonstrating Positive Response in Lupus | 50 | 1 |
| May 23, 2016: KPI Therapeutics to Present Updated Dalazatide Study Data in Lupus | 51 | 1 |
| May 12, 2016: KPI Therapeutics Presents Dalazatide Plaque Psoriasis Data at Dermatology Conference | 51 | 1 |
| Feb 08, 2016: KPI Therapeutics Initiates Research Program In Skin Diseases | 51 | 1 |
| Feb 08, 2016: KPI Therapeutics Initiates Research Program In Eye Diseases | 52 | 1 |
| Nov 10, 2015: Kineta, Seattle Children s Research Institute Present New Data Demonstrating Positive, Predictive Responses to Dalazatide In Lupus | 52 | 1 |
| Nov 09, 2015: Kineta Presents New Data Demonstrating Positive, Predictive Responses to Dalazatide in Psoriasis Patients and in Lupus, ANCA Vasculitis Studies at American College of Rheumatology Annual Meeting | 53 | 1 |
| Aug 08, 2015: Kineta Presents Updated Data on Dalazatide Clinical Trial at 12th World Congress on Inflammation | 54 | 1 |
| Jun 17, 2015: ACT Research Suggests Role for Dalazatide in Blocking T Cells from Patients with Lupus | 54 | 1 |
| Jun 09, 2015: Kineta To Give Update On Dalazatide Clinical Trial Results At BIO International Meeting | 55 | 1 |
| Jun 05, 2015: Sevion Therapeutics to Present at International Antibody Meeting | 55 | 1 |
| May 05, 2015: Kineta Announces Promising Top-line Clinical Results for Dalazatide; Target Implicated in Broad Array of Autoimmune Diseases | 56 | 1 |
| May 04, 2015: Sevion Therapeutics Presents Cow Antibody Platform at PEGS 2015 | 57 | 1 |
| Apr 21, 2015: Kineta, University of Groningen Present New, Positive Data for Dalazatide in ANCA Vasculitis, an Orphan Disease | 58 | 1 |
| Mar 19, 2015: Kineta s ShK-186 Shows Encouraging Early Results as Potential Therapy for Autoimmune Eye Diseases | 58 | 2 |
| Appendix | 60 | 2 |
| Methodology | 60 | 1 |
| Coverage | 60 | 1 |
| Secondary Research | 60 | 1 |
| Primary Research | 60 | 1 |
| Expert Panel Validation | 60 | 1 |
| Contact Us | 60 | 1 |
| Disclaimer | 61 | 1 |